Literature DB >> 17611576

A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice.

Janet A Fairley1, Christopher T Burnett, Chang-Ling Fu, David L Larson, Matthew G Fleming, George J Giudice.   

Abstract

Bullous pemphigoid (BP) is an autoimmune disease characterized by subepidermal blistering. Based on previous work, IgG autoantibodies directed against BP180 are thought to be the primary pathogenic agent in BP. In addition to these IgG autoantibodies, however, most BP patients produce IgE class autoantibodies that also react with BP180, and total IgE levels are often elevated in this disease. To directly test whether BP IgE is pathogenic, 6 ng of total IgE isolated from two BP and two normal sera were injected into human skin grafted onto athymic, nude mice. Twenty-four hours after injection, erythematous, elevated plaques were observed in all human skin grafts receiving BP IgE (n=11), but not control IgE (n=9). Histologic and ultrastructural examination of the lesions showed engorgement of blood vessels and a dermal infiltrate composed of neutrophils, eosinophils, and mast cells, many of which were degranulated. At a higher dose of BP IgE (47 ng), histological separation of the epidermis from the dermis was observed in two of the three grafts. The BP IgE-induced erythematous plaques were reminiscent of those clinically seen in BP. This provides early evidence of a direct demonstration of a pathogenic role for IgE class autoantibodies in a human autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17611576     DOI: 10.1038/sj.jid.5700958

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  43 in total

Review 1.  Non-infectious environmental antigens as a trigger for the initiation of an autoimmune skin disease.

Authors:  Ye Qian; Donna A Culton; Joseph S Jeong; Nicole Trupiano; Jesus G Valenzuela; Luis A Diaz
Journal:  Autoimmun Rev       Date:  2016-07-08       Impact factor: 9.754

2.  Type XVII collagen (BP180) can function as a cell-matrix adhesion molecule via binding to laminin 332.

Authors:  F Van den Bergh; S L Eliason; G J Giudice
Journal:  Matrix Biol       Date:  2010-10-26       Impact factor: 11.583

3.  Pregnant women have increased incidence of IgE autoantibodies reactive with the skin and placental antigen BP180 (type XVII collagen).

Authors:  Megan H Noe; Kelly A N Messingham; Debra S Brandt; Janet I Andrews; Janet A Fairley
Journal:  J Reprod Immunol       Date:  2010-05-14       Impact factor: 4.054

Review 4.  Mechanisms of Disease: Pemphigus and Bullous Pemphigoid.

Authors:  Christoph M Hammers; John R Stanley
Journal:  Annu Rev Pathol       Date:  2016-02-22       Impact factor: 23.472

Review 5.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

Review 6.  Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid.

Authors:  K A N Messingham; H M Holahan; J A Fairley
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

7.  Eosinophil localization to the basement membrane zone is autoantibody- and complement-dependent in a human cryosection model of bullous pemphigoid.

Authors:  Kelly N Messingham; Jeffrey W Wang; Heather M Holahan; Rupasree Srikantha; Samantha C Aust; Janet A Fairley
Journal:  Exp Dermatol       Date:  2015-11-23       Impact factor: 3.960

8.  Treatment of subepidermal immunobullous diseases.

Authors:  Donna A Culton; Luis A Diaz
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

9.  Diagnosis and clinical severity markers of bullous pemphigoid.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  F1000 Med Rep       Date:  2009-02-24

10.  A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid.

Authors:  Kelly A N Messingham; Megan H Noe; Marisa A Chapman; George J Giudice; Janet A Fairley
Journal:  J Immunol Methods       Date:  2009-05-05       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.